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CONFERENCE SUMMARY
HIV Research for Prevention 2018: From Research to Impact
Conference Summary and Highlights
Barbara L. Shacklett,1 Julia` Blanco,2,3 Lisa Hightow-Weidman,4 Nyaradzo Mgodi,5 Jose´ Alcamı´,6
Susan Buchbinder,7 Mike Chirenje,5 Smritee Dabee,8 Mamadou Diallo,9 Kostyantyn Dumchev,10
Carolina Herrera,11 Matthew E. Levy,12 Enrique Martin Gayo,13 Nigel Aminake Makoah,14 Kate M. Mitchell,15,16
Kenneth Mugwanya,17 Krishnaveni Reddy,18 Maria Luisa Rodrı´guez,2 Marta Rodriguez-Garcia,19
Chelsea L. Shover,20 Tripti Shrivastava,21 Georgia Tomaras,22 Michiel Van Diepen,8 Monika Walia,23
Mitchell Warren,24 Amapola Manrique,25 Bargavi Thyagarajan,25 and Tamara Torri26
Abstract
The HIV Research for Prevention (HIVR4P) conference is dedicated to advancing HIV prevention research,
responding to a growing consensus that effective and durable prevention will require a combination of approaches
as well as unprecedented collaboration among scientists, practitioners, and community workers from different
fields and geographic areas. The conference theme in 2018, ‘‘From Research to Impact,’’ acknowledged an
increasing focus on translation of promising research findings into practical, accessible, and affordable HIV
prevention options for those who need them worldwide. HIVR4P 2018 was held in Madrid, Spain, on 21–25
October, with >1,400 participants from 52 countries around the globe, representing all aspects of HIV prevention
research and implementation. The program included 137 oral and 610 poster presentations. This article presents a
brief summary of highlights from the conference. More detailed information, complete abstracts as well as
webcasts and daily Rapporteur summaries may be found on the conference website.
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Introduction
Opening plenary talks, delivered by Linda-GailBekker (Abstract PL01.01)1 (recipient of the 2018
Desmond Tutu Award for HIV Prevention Research and
Human Rights), Anthony Fauci (Abstract PL01.03),1 and
Sheena McCormack (Abstract PL01.02),1 provided impor-
tant perspectives on the major challenges facing the HIV
prevention field. Presenting his long-term vision for control
of the pandemic, Dr. Fauci introduced the image of two roads
converging toward eventual control. The two roads represent
vaccine-based and nonvaccine-based strategies, with the latter
group including condom use, voluntary medical male cir-
cumcision (VMMC), prevention of mother-to-child trans-
mission, treatment as prevention (TasP), and pre-exposure
prophylaxis (PrEP). He emphasized that control of the pan-
demic appears to be a more realistic goal at this time, rather
than complete eradication, and that a vaccine capable of
reaching 50%–60% efficacy, used in combination with other
prevention and treatment strategies, could help attain this goal.
While the number of new HIV infections is declining globally,
key populations such as adolescent girls and young women in
southern Africa, female sex workers, men who have sex with
men (MSM), the Lesbian Gay Bisexual Transgender Queer
community and people who inject drugs are still dispropor-
tionately affected by the epidemic.2 These plenary talks set the
stage for the remainder of the conference, which also focused
on vaccine-based and nonvaccine-based strategies for HIV
prevention. A list of HIV prevention clinical trials discussed
at HIV Research for Prevention (HIVR4P) 2018 is presented
in Table 1.
More Signposts on the Road to HIV Vaccines
The journey of discovery toward an effective HIV vaccine
may be longer than many imagined, but the consensus from
this conference was that there are now more signposts than
ever to guide the way. HIVR4P included a wealth of presenta-
tions exploring our growing knowledge of immune responses,
updates from studies currently underway, views of strategies to
improve the results of RV144, and an examination of the
growing pipeline of vaccine approaches. These include broadly
neutralizing antibodies (bNAbs) and CD8+T-cell pathways to a
vaccine, and DNA, RNA, and mosaic strategies. As concluded
by John Mascola (Abstract PL04.04)1 in his final plenary talk,
‘‘The path [to vaccine development] will not be short, it will
probably be bumpy, but reaching the final goal is likely.’’
Current vaccine studies fall into three broad categories: (i)
those following the RV144 trial and aimed at induction of du-
rable antibody-dependent cell-mediated cytotoxicity (ADCC)-
promoting antibodies; (ii) those aimed at eliciting bNAbs, either
by mimicking Env vulnerability sites or by driving immune
responses from germline B-cells; and (iii) those aiming to elicit
robust T-cell responses, including those directed toward po-
tentially protective but subdominant epitopes.
RV144 follow-up
As described by Linda-Gail Bekker (Abstract PL01.01)1
in an Opening Plenary talk, the partial protection observed in
RV144 has led to several subsequent vaccine trials. RV144
remains the only vaccine trial to demonstrate efficacy against
HIV acquisition, with antibodies directed against the V1V2
region of gp120 and ADCC-mediating antibodies correlating
with lower acquisition rates, and plasma envelope (Env)-
specific IgA antibodies correlating with risk.3,4 HVTN 100
was a phase 1/2 study in low-risk, HIV-uninfected South
Africans combining ALVAC-HIV and subtype C gp120 ad-
juvanted with MF59. As reported by Xiaoying Shen (Ab-
stract OA02.03),1 HVTN 100 elicited anti-V1V2 binding
antibody responses and antibodies capable of mediating
phagocytosis and ADCC; however, V1V2 antibody magni-
tude and breadth were lower than those reported in RV144
and HVTN 097. A comparison of HVTN 100 and HVTN 111,
presented by Zoe Moodie (Abstract OA02.04LB),1 revealed
induction of higher anti-V1V2 IgG titers, NAb titers, and
CD4+ T-cell responses with DNA prime compared with AL-
VAC prime, supporting further evaluation of DNA in prime-
boost regimens with Env proteins. Early data from HVTN 100
paved the way for HVTN 702 (UHAMBO), a randomized,
double-blind study that is currently recruiting participants, and
will test immunogens optimized for prevention of Clade C
infections.
Novel immunogen design
In a comprehensive overview, Rogier Sanders (Abstract
PL03.03)1 summarized current immunogen design efforts,
outlining four hypotheses driving these efforts. The ‘‘native
trimer’’ hypothesis predicts that a stable structural and antigenic
mimic of the native, cleaved Env trimer will induce neutralizing
antibodies. This is being tested with a third-generation native-
like trimer, BG505 SOSIP.664, in the vaccine trial designated
as W001. The second or ‘‘lineage immunogen’’ hypothesis is
based on the observation that bNAbs do not emerge immedi-
ately in response to one antigen, but instead require coevolution
of the virus and the antibody response. Therefore, sequential
immunization with a series of Envs mimicking those longitu-
dinally produced in individuals who develop bNAbs over time
may induce similar antibodies. This is being tested by CHAVI-
ID using sequential immunogens derived from CH505 gp120
and SOSIP trimers.
In a related approach, Jose´ Alcami, Eloisa Yuste, and
colleagues (Abstract SY01.03)1 have synthesized Env tri-
mers from very rare ‘‘acute neutralizers’’; these will be tested
in a European trial beginning in 2019 within the EAVI2020
project. The third or ‘‘germline-targeting’’ hypothesis pre-
dicts that Env immunogens engineered to target germline
precursors will effectively prime bNAbs. Leading immuno-
gens in this category are the eOD-GT8 60-mer described by
Bill Schief (Abstract SY01.05),1 426cTM, and BG505
GT1.1, all of which are planned for upcoming clinical trials.
The fourth or ‘‘epitope-focusing’’ hypothesis reviewed by
Dr. Sanders reasons that Env vaccines contain many poten-
tially distracting epitopes; accordingly, priming with a highly
focused immunogen might produce a more focused response.
The leading immunogen in this category, the fusion peptide-
based immunogen FP8_v1-rTTHC, will begin clinical trials
in 2019 led by the NIH VRC.
CONFERENCE SUMMARY AND HIGHLIGHTS 599
T
a
b
l
e
1
.
H
IV
P
r
e
v
e
n
t
io
n
C
l
in
ic
a
l
T
r
ia
l
s
t
h
a
t
a
r
e
D
e
sc
r
ib
e
d
in
t
h
is
C
o
n
fe
r
e
n
c
e
S
u
m
m
a
r
y
T
ri
a
l
In
te
rv
en
ti
o
n
P
h
a
se
S
tr
a
te
g
y
T
ri
a
l
si
te
s
P
o
p
u
la
ti
o
n
S
ta
tu
s
A
M
P
S
T
U
D
Y
A
n
ti
b
o
d
y
in
fu
si
o
n
2
b
In
tr
av
en
o
u
s
in
fu
si
o
n
o
f
h
u
m
an
m
A
b
,
V
R
C
0
1
B
o
ts
w
an
a,
K
en
y
a,
M
al
aw
i,
M
o
za
m
b
iq
u
e,
S
o
u
th
A
fr
ic
a,
T
an
za
n
ia
,
Z
im
b
ab
w
e
W
o
m
en
,
ag
es
1
8
–
5
0
O
n
g
o
in
g
H
V
T
N
7
0
3
/H
P
T
N
0
8
1
A
M
P
S
T
U
D
Y
A
n
ti
b
o
d
y
in
fu
si
o
n
2
b
In
tr
av
en
o
u
s
in
fu
si
o
n
o
f
h
u
m
an
m
A
b
,
V
R
C
0
1
B
ra
zi
l,
P
er
u
,
S
w
it
ze
rl
an
d
,
U
n
it
ed
S
ta
te
s
M
en
(M
S
M
)
an
d
tr
an
sg
en
d
er
p
er
so
n
s,
ag
es
1
8
–
5
0
O
n
g
o
in
g
H
V
T
N
7
0
4
/H
P
T
N
0
8
5
A
S
P
IR
E
(M
T
N
0
2
0
)
V
ag
in
al
ri
n
g
3
D
P
V
ri
n
g
M
al
aw
i,
S
o
u
th
A
fr
ic
a,
U
g
an
d
a,
Z
im
b
ab
w
e
W
o
m
en
,
ag
es
1
8
–
4
5
Ju
n
e
2
0
1
5
C
H
A
P
S
P
rE
P
2
O
n
-d
em
an
d
o
ra
l
T
A
F
/F
T
C
co
m
p
ar
ed
w
it
h
T
D
F
(T
D
F
/F
T
C
)
fo
r
in
se
rt
iv
e
se
x
S
o
u
th
A
fr
ic
a,
U
g
an
d
a,
Z
im
b
ab
w
e
M
en
,
ag
es
1
3
–
2
4
O
n
g
o
in
g
D
IS
C
O
V
E
R
P
rE
P
3
D
ai
ly
,
o
ra
l
T
A
F
/F
T
C
co
m
p
ar
ed
w
it
h
T
D
F
(T
D
F
/F
T
C
)
A
u
st
ri
a,
C
an
ad
a,
D
en
m
ar
k
,
F
ra
n
ce
,
G
er
m
an
y
,
Ir
el
an
d
,
It
al
y
,
T
h
e
N
et
h
er
la
n
d
s,
S
p
ai
n
,
U
n
it
ed
K
in
g
d
o
m
,
U
n
it
ed
S
ta
te
s
M
en
(M
S
M
)
an
d
T
G
W
,
ag
es
‡1
8
O
n
g
o
in
g
E
C
H
O
(E
v
id
en
ce
fo
r
C
o
n
tr
ac
ep
ti
v
e
O
p
ti
o
n
s
an
d
H
IV
O
u
tc
o
m
es
)
st
u
d
y
H
o
rm
o
n
al
co
n
tr
ac
ep
ti
v
es
an
d
H
IV
D
M
P
A
,
L
N
G
S
o
u
th
A
fr
ic
a,
K
en
y
a,
S
w
az
il
an
d
,
Z
am
b
ia
W
o
m
en
,
ag
es
1
6
–
3
5
O
n
g
o
in
g
H
P
T
N
0
4
6
T
as
P
3
O
ra
l
N
ev
ir
ap
in
e
S
o
u
th
A
fr
ic
a,
T
an
za
n
ia
,
U
g
an
d
a,
Z
im
b
ab
w
e
P
re
g
n
an
t
w
o
m
en
‡1
8
an
d
th
ei
r
in
fa
n
ts
C
o
m
p
le
te
d
N
o
v
em
b
er
2
0
1
1
H
P
T
N
0
7
7
P
rE
P
2
a
L
o
n
g
-a
ct
in
g
,
in
je
ct
ab
le
ca
b
o
te
g
ra
v
ir
B
ra
zi
l,
M
al
aw
i,
S
o
u
th
A
fr
ic
a,
U
n
it
ed
S
ta
te
s
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
6
5
C
o
m
p
le
te
d
Ju
ly
2
0
1
8
H
P
T
N
0
8
3
P
rE
P
3
In
je
ct
ab
le
ca
b
o
te
g
ra
v
ir
L
A
fo
r
P
rE
P
A
rg
en
ti
n
a,
B
ra
zi
l,
In
d
ia
,
P
er
u
,
S
o
u
th
A
fr
ic
a,
T
h
ai
la
n
d
,
V
ie
tn
am
,
U
n
it
ed
S
ta
te
s
M
en
(M
S
M
)
an
d
T
G
W
,
ag
es
‡1
8
O
n
g
o
in
g
H
P
T
N
0
8
4
P
rE
P
3
L
o
n
g
-a
ct
in
g
in
je
ct
ab
le
ca
b
o
te
g
ra
v
ir
co
m
p
ar
ed
w
it
h
d
ai
ly
o
ra
l
T
D
F
/F
T
C
B
o
ts
w
an
a,
K
en
y
a,
S
o
u
th
A
fr
ic
a,
U
g
an
d
a,
Z
im
b
ab
w
e
W
o
m
en
,
ag
es
1
8
–
4
5
O
n
g
o
in
g
H
V
T
N
0
9
7
V
ac
ci
n
e
1
b
A
L
V
A
C
an
d
A
ID
S
V
A
X
B
/E
,
te
ta
n
u
s
to
x
o
id
v
ac
ci
n
e
an
d
h
ep
at
it
is
B
v
ac
ci
n
e
S
o
u
th
A
fr
ic
a
W
o
m
en
an
d
m
en
,
ag
es
1
8
–
4
0
C
o
m
p
le
te
d
F
eb
ru
ar
y
2
0
1
5
H
V
T
N
1
0
0
V
ac
ci
n
e
1
/2
A
L
V
A
C
p
ri
m
e
an
d
b
iv
al
en
t
su
b
ty
p
e
C
g
p
1
2
0
/M
F
5
9
b
o
o
st
S
o
u
th
A
fr
ic
a
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
4
0
C
o
m
p
le
te
d
A
u
g
u
st
2
0
1
8
H
V
T
N
1
0
6
V
ac
ci
n
e
1
N
at
-B
/C
O
N
-S
/M
o
sa
ic
E
n
v
D
N
A
p
ri
m
e,
M
V
A
-C
D
M
R
b
o
o
st
S
w
it
ze
rl
an
d
,
U
n
it
ed
S
ta
te
s
W
o
m
en
an
d
m
en
,
ag
es
1
8
–
5
0
O
n
g
o
in
g
H
V
T
N
1
1
1
V
ac
ci
n
e
1
S
u
b
ty
p
e
C
D
N
A
p
ri
m
e
an
d
su
b
ty
p
e
C
g
p
1
2
0
/M
F
5
9
b
o
o
st
S
o
u
th
A
fr
ic
a,
T
an
za
n
ia
,
Z
am
b
ia
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
4
0
O
n
g
o
in
g
H
V
T
N
7
0
2
V
ac
ci
n
e
2
b
/3
A
L
V
A
C
p
ri
m
e
an
d
b
iv
al
en
t
su
b
ty
p
e
C
g
p
1
2
0
/M
F
5
9
b
o
o
st
S
o
u
th
A
fr
ic
a
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
3
5
O
n
g
o
in
g
(c
o
n
ti
n
u
ed
)
600
T
a
b
l
e
1
.
(C
o
n
t
in
u
e
d
)
T
ri
a
l
In
te
rv
en
ti
o
n
P
h
a
se
S
tr
a
te
g
y
T
ri
a
l
si
te
s
P
o
p
u
la
ti
o
n
S
ta
tu
s
H
V
T
N
7
0
5
V
ac
ci
n
e
2
b
A
d
2
6
.M
o
s4
.H
IV
p
ri
m
e,
C
la
d
e
C
g
p
1
4
0
b
o
o
st
M
al
aw
i,
M
o
za
m
b
iq
u
e,
S
o
u
th
A
fr
ic
a,
Z
am
b
ia
,
Z
im
b
ab
w
e
W
o
m
en
,
ag
es
1
8
–
3
5
O
n
g
o
in
g
M
T
N
0
3
0
/I
P
M
0
4
1
M
ic
ro
b
ic
id
es
1
D
P
V
/L
N
G
v
ag
in
al
ri
n
g
s
U
n
it
ed
S
ta
te
s
W
o
m
en
,
ag
es
1
8
–
4
5
C
o
m
p
le
te
d
A
u
g
u
st
2
0
1
7
P
ro
m
is
e
st
u
d
y
T
as
P
3
O
ra
l
Z
D
V
,
N
ev
ir
ap
in
e
T
ru
v
ad
a,
L
am
iv
u
d
in
e-
Z
D
V
,
L
o
p
in
av
ir
-
ri
to
n
av
ir
In
d
ia
,
M
al
aw
i,
S
o
u
th
A
fr
ic
a,
T
an
za
n
ia
,
U
g
an
d
a,
Z
am
b
ia
,
Z
im
b
ab
w
e
P
re
g
n
an
t,
p
o
st
p
ar
tu
m
w
o
m
en
an
d
th
ei
r
ch
il
d
re
n
C
o
m
p
le
te
d
S
ep
te
m
b
er
2
0
1
6
Q
u
at
ro
st
u
d
y
V
ag
in
al
d
el
iv
er
y
fo
rm
s—
g
el
,
in
se
rt
,
fi
lm
,
o
r
IV
R
P
la
ce
b
o
d
el
iv
er
y
th
ro
u
g
h
h
y
d
ro
x
y
et
h
y
l
ce
ll
u
lo
se
g
el
,
v
ag
in
al
in
se
rt
,
fi
lm
,
o
r
IV
R
S
o
u
th
A
fr
ic
a,
Z
im
b
ab
w
e
W
o
m
en
,
ag
es
1
8
–
3
0
C
o
m
p
le
te
d
S
ep
te
m
b
er
2
0
1
7
R
IN
G
S
T
U
D
Y
IP
M
0
2
7
M
ic
ro
b
ic
id
es
3
D
P
V
v
ag
in
al
ri
n
g
S
o
u
th
A
fr
ic
a,
U
g
an
d
a
W
o
m
en
,
ag
es
1
8
–
4
5
C
o
m
p
le
te
d
D
ec
em
b
er
2
0
1
6
R
V
1
4
4
V
ac
ci
n
e
3
A
L
V
A
C
p
ri
m
e
an
d
V
ax
G
en
g
p
1
2
0
B
/E
b
o
o
st
T
h
ai
la
n
d
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
3
0
C
o
m
p
le
te
d
Ju
n
e
2
0
0
9
R
V
2
1
7
E
ar
ly
C
ap
tu
re
H
IV
C
o
h
o
rt
S
tu
d
y
(E
C
H
O
)
P
ro
sp
ec
ti
v
e
n
at
u
ra
l
h
is
to
ry
st
u
d
y
fo
ll
o
w
in
g
h
ig
h
-r
is
k
v
o
lu
n
te
er
s
K
en
y
a,
T
an
za
n
ia
,
T
h
ai
la
n
d
,
U
g
an
d
a
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
5
0
,
at
h
ig
h
ri
sk
o
f
H
IV
-1
in
fe
ct
io
n
C
o
m
p
le
te
d
S
ep
te
m
b
er
2
0
1
8
T
se
p
am
o
st
u
d
y
T
as
P
3
D
T
G
,
F
T
C
/T
A
F
o
r
D
T
G
,
F
T
C
/T
D
F
o
r
ef
av
ir
en
z/
F
T
C
/T
D
F
B
o
ts
w
an
a
P
re
g
n
an
t
w
o
m
en
,
ag
es
‡1
8
an
d
th
ei
r
in
fa
n
ts
O
n
g
o
in
g
U
C
h
o
o
se
C
o
n
tr
ac
ep
ti
v
e
m
et
h
o
d
s
as
p
ro
x
y
fo
r
H
IV
p
re
v
en
ti
o
n
m
et
h
o
d
s
In
je
ct
ab
le
N
u
r-
Is
te
ra
te
,
in
tr
av
ag
in
al
N
u
v
ar
in
g
an
d
d
ai
ly
,
o
ra
l
T
ri
p
h
as
il
ta
b
le
t
S
o
u
th
A
fr
ic
a
W
o
m
en
,
ag
es
1
6
–
1
7
O
n
g
o
in
g
W
0
0
1
V
ac
ci
n
e
1
R
ec
o
m
b
in
an
t
B
G
5
0
5
S
O
S
IP
g
p
1
4
0
p
ro
te
in
tr
im
er
K
en
y
a,
U
n
it
ed
S
ta
te
s
M
en
an
d
w
o
m
en
,
ag
es
1
8
–
5
0
O
n
g
o
in
g
D
M
P
A
,
d
ep
o
t
m
ed
ro
x
y
p
ro
g
es
te
ro
n
e
ac
et
at
e;
D
P
V
,
d
ap
iv
ir
in
e;
D
T
G
,
d
o
lu
te
g
ra
v
ir
;
E
F
V
,
ef
av
ir
en
z;
F
T
C
,
em
tr
ic
it
ab
in
e;
IV
R
,
in
tr
av
ag
in
al
ri
n
g
;
L
N
G
,
le
v
o
n
o
rg
es
tr
el
;
M
S
M
,
m
en
w
h
o
h
av
e
se
x
w
it
h
m
en
;
P
rE
P
,
p
re
-e
x
p
o
su
re
p
ro
p
h
y
la
x
is
;
T
A
F
,
te
n
o
fo
v
ir
al
af
en
am
id
e;
T
as
P
,
tr
ea
tm
en
t
as
p
re
v
en
ti
o
n
;
T
D
F
,
te
n
o
fo
v
ir
d
is
o
p
ro
x
il
fu
m
ar
at
e;
T
G
W
,
tr
an
sg
en
d
er
w
o
m
en
.
601
Mosaic immunogen approaches
and T-cell-based vaccines
In HVTN 106, a phase 1 study reported by Nicole Frahm
(Abstract OA07.01),1 a trivalent group M T-cell mosaic DNA
vaccine was compared with DNA sequences from transmit-
ted/founder clade B.1059, or group M centralized sequences
(ConS). The magnitude of Env-specific CD4+T-cell responses
was higher in the group receiving the mosaic vaccine, and
response breadth was also greater in the group primed with
mosaic DNA. Current and future studies utilizing mosaic
immunogens include the phase 2b HVTN 705 study (IM-
BOKODO), which will utilize Ad26.Mos4.HIV mosaic an-
tigens combined with trimeric Clade C gp140 protein. This
strategy has shown significant protection in nonhuman pri-
mates and is demonstrably immunogenic in humans. Talks
by Wendy Burgers (Abstract SY06.02)1 and Christian
Brander (Abstract SY06.03)1 reviewed the role of T-cells
in vaccine-mediated protection. Studies to date suggest a
role for CD4+ T-cells in supporting effective antibody de-
velopment, and work from Louis Picker’s laboratory on the
cytomegalovirus-vectored simian immune deficiency vac-
cine in rhesus macaques indicates a critical role for vaccine-
induced, nonclassical CD8+ T-cell responses, restricted by
Major Histocompatibility Complex class II and class I histo-
compatibility antigen, alpha chain E. There remain gaps in our
understanding of the role of T-cells in protection from and/or
clearance of infection, as well as of how best to measure T-cell
responses, and what tissues should be sampled. Michael Gale
(Abstract SY08.04)1 presented transcriptome data from ani-
mals in the RhCMV/SIV vaccine study, showing clear segre-
gation between protected and unprotected animals by 3 days
postvaccination.
Antibody-Mediated Prevention
Recombinant forms of bNAbs are known to be safe when
administered by infusion to uninfected individuals, also
known as passive immunization. Lynn Morris (Abstract
SY01.02)1 provided an overview of ongoing and planned
antibody-mediated prevention (AMP) studies. Two studies
are currently underway to evaluate the efficacy of the VRC01
bNAb: HVTN 704/HPTN 085, which focuses on MSM and
transgender individuals in the Americas, and HVTN 703/
HPTN 081, which enrolled women in sub-Saharan Africa. As
mentioned previously, there is also a pipeline of double and
triple bNAb combinations, with improved breadth and po-
tency toward acute-early Clade C viruses, which will be
tested in future trials. The current AMP studies are seen as
pivotal proof-of-concept trials; if successful, results of these
trials will strengthen the rationale for bNAb-based vaccines,
and pave the way for improved prevention trials with passive
administration of bNAbs.
Importantly, AMP strategies can also be used to pre-
vent mother-to-child transmission. Ann Hessell (Abstract
OA13.06LB)1 extended her earlier findings that postexposure
prophylaxis with passive infusion of bNAbs is able to protect
newborn macaques from oral exposure to SHIV. Protection is
time- and dose dependent, and is most effective when the
bNAbs are present before the virus is widely disseminated
throughout the body.
New data presented at HIVR4P described different im-
proved AMP strategies currently under development, including
those relying on vector-based delivery, such as adeno-
associated virus-based strategies presented by Jose´ Martı´nez-
Navı´o (Abstract OA13.05)1; or those modulating antibody
interaction with neonatal Fc receptors to increase plasma
half-life; antibody combinations with different specificities;
and synthetic bi- or trispecific antibodies. The latter ap-
proach was exemplified by antibody mimetics such as newly
designed ankyrin repeat proteins (DARPins) presented by
Matthias Glo¨gl (Abstract PD01.01)1 and a new engineered
bispecific antibody, which successfully protected human-
ized mice from HIV acquisition. These antibodies, devel-
oped by Zhiwei Chen (Abstract SY01.01),1 recognize both
gp120 and CD4.
Advances in Basic Science
HIV transmission and dissemination
New findings presented at HIVR4P focused on aspects of
mucosal HIV transmission and early dissemination. Thomas
Hope (Abstract PL02.01)1 described the use of novel imag-
ing approaches to answer questions about early HIV trans-
mission, mucosal reservoirs during antiretroviral therapy
(ART), antibody distribution, and PrEP efficacy in an in vivo
nonhuman primate model. His group has been at the forefront
of developing and applying new technologies to localize and
quantify viral reservoirs, particularly within mucosal tissues.
In a session focused on Mucosal Models of Prevention, Ro-
semary Bastian (Abstract OA06.01)1 showed that binding
affinity between HIV-specific IgG antibodies and various
mucins correlated with in vitro enhancement of neutralization
potency. Marta Rodriguez-Garcia (Abstract OA06.02)1 ex-
plored how neutrophils from the female genital tract capture
HIV through release of extracellular traps.
Manish Sagar (Abstract SY02.01)1 identified a vaginal
resident CD1a+ classical dendritic cell (DC) population able to
support CCR5-tropic but not CXCR4-tropic HIV-1 replication
in vitro, suggesting that these cells might play an active role in
the selection of transmitted viral variants during sexual HIV
acquisition. Andrew Harman (Abstract SY02.02)1 provided
evidence of CD11c+ DCs highly susceptible to CCR5-tropic
HIV-1 in male and female genital mucosa. Data from Eric Arts
(Abstract SY02.03)1 supported a role of migrating DC select-
ing and disseminating virus from mucosal sites. He also pro-
vided evidence for selection of specific patterns of glycosylated
viruses, raising the question of whether active recruitment/
infection of lectin-expressing DC could be a mechanism for
preferential transmission of viral variants. Finally, Alexandra
Schuetz (Abstract SY02.04)1 provided new data on the impact
of early treatment on HIV replication and mucosal T-cells in an
acute infection cohort from Thailand. Patients treated begin-
ning at Fiebig stage I had lower levels of immune activation,
but interruption of ART led to viral rebound in patients treated
at all stages.
Reporting on Lake Victoria fishing communities with a high
prevalence of both HIV and Schistosoma mansoni, Rupert
Kaul (Abstract OA17.02LB)1 showed that schistosome treat-
ment with Praziquantel reduced HIV entry into cervical and
blood CD4+ T-cells. Morgane Rolland (Abstract OA17.03)1
used phylodynamic analysis and modeling of viral growth
rates to more accurately assess the duration of the eclipse phase
of HIV infection. In the RV217 HIV-1 acute infection cohort,
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the eclipse phase was estimated to last 6 days for infections by
single founders, with no obvious effect linked to virus subtype
or gender. In oral transmission studies using SIVmac251 to
model neonatal transmission in rhesus macaques, Roslyn
Taylor (Abstract OA17.05)1 found that the entire digestive
tract is susceptible to replicative viral infection, and that the
majority of infected cells are T-cells. Nicole Naiman (Abstract
OA17.06)1 presented data from mother–infant pairs collected
in Nairobi during the 1990s in a breastfeeding study. IgG
binding to the gp41 ectodomain was associated with increased
risk of mother-to-child transmission.
A role for the microbiome in HIV susceptibility?
Finally, several speakers discussed the role of microbial
diversity in HIV susceptibility. Heather Jaspan (Abstract
SY10.01)1 reported that higher diversity was consistently
associated with increased HIV risk, as were inflammation and
recruitment of target cells to the mucosa. Connie Celum
(Abstract SY10.02)1 reported on increasing rates of other
sexually transmitted pathogens, notably Chlamydia tracho-
matis and Neisseria gonorrhoeae infection in North America,
especially in MSM, and emphasized the need for more in-
novative ways to address this problem. Cara Wilson (Ab-
stract SY10.04)1 reported on the use of in vitro systems to
model the complex interactions between immune cells, HIV,
and intestinal microbiota. Her group found that mucosal
butyrate-producing bacteria were associated with reduced
CD4+ T-cell proliferation and activation.
Mucosal microbiomes influence susceptibility to disease
and response to treatment. There is strong evidence that
vaginal dysbiosis increases risk of HIV acquisition. How-
ever, the relationship between hormonal contraception and
HIV susceptibility is less clear. Studies of multiple con-
traception methods have found that hormonal contra-
ception optimizes vaginal bacteria over time (as measured
by decreased Nugent score). Sharon Achilles (Abstract
PL02.03)1 argued that these findings rule out dysbiosis as a
pathway for hormonal contraception to increase HIV risk.
Two other possible mechanisms are changes in bleeding
patterns and decreased condom use. For the vaginal ring
(NuvaRing), 3 months of data demonstrated a decrease in
dysbiosis, though accumulation of biomass on the ring was
positively associated with dysbiosis. Considering these
findings, Dr. Achilles identified priority research questions:
What happens to the vaginal microbiome when women have
more bleeding, even if it is light spotting (as occurs in
some women after starting hormonal contraception)? What
happens to microbiome with vaginally delivered drugs?
What are the longitudinal impacts of intrauterine devices
(IUDs) or implants on the vaginal microbiome, and how
does the microbiome alter the metabolism and efficacy of
these devices?
Contraception, pregnancy and HIV risk
Hormonal contraception products such as injectable depot
medroxyprogesterone acetate (DMPA) and norethisterone
enanthate (NET-EN) may modulate HIV acquisition risk;
however, the biological mechanisms at play remain incom-
pletely understood. Chanel Avenant (Abstract OA12.01)1
showed that both MPA and luteal phase hormones increased
HIV-1 infection of peripheral blood mononuclear cell and
TZM-bl cells in the laboratory. In the case of MPA, the
mechanism involved increased activation of CD4+ T-cells
and increased expression of CCR5, mediated through the
glucocorticoid receptor. In a related study, Taguma Matubu
(Abstract OA12.04)1 reported that DMPA, but not NET-EN,
decreased T-cell activation in response to polyclonal stimu-
lation, suggesting a possible window of immune suppression
at peak MPA levels. This ‘‘window’’ could translate to
heightened susceptibility to HIV infection. The ongoing
ECHO trial of DMPA, the Jadelle implant, and the copper
IUD to evaluate whether any of the three methods might
actually increase the risk of HIV acquisition was described at
the conference, and results are expected in mid-2019.
A phase 1 pharmacokinetic (PK) study of a dapivirine (DPV)
and levonorgestrel (LNG) vaginal ring for combined pre-
vention of HIV and pregnancy risk [MTN-030/IPM 041,
presented by Sharon Achilles (Abstract OA12.02LB)1]
demonstrated that this ring was safe, well tolerated, and re-
sulted in adequate DPV and LNG exposure.
Focusing on ‘‘safe conception’’ strategies for couples
living with HIV, Renee Heffron (Abstract OA12.05)1 re-
ported on a pilot study of HIV prevention in the context of
pregnancy optimization for HIV serodiscordant couples in
Kenya. Couples utilized a variety of safe sex strategies, in-
cluding ART, PrEP, VMMC, or timed condomless sex acts.
Encouragingly, the study detected no new HIV infections
among the 74 couples enrolled.
PrEP Comes of Age
PrEP impact, PrEP access, and the possibility that PrEP
works differently for different people were running themes
throughout HIVR4P 2018. Conference sessions and presen-
tations looked at the current and potential future impact of
PrEP, scale-up options, and opportunities and challenges of
building social, political, and financial support to make PrEP
available for those who could benefit most. Abstracts focused
on PrEP acceptability, mathematical modeling of PrEP tar-
geting, costs and benefits, and a host of presentations on
emerging PrEP drugs and delivery options that could greatly
increase the future impact of PrEP were also discussed.
Jared Baeten (Abstract OA23.01)1 reported on HIV in-
cidence in persons using Truvada [emtricitabine (FTC)/
tenofovir disoproxil fumarate (TDF)] in a total of 46 PrEP
demonstration projects worldwide, involving >10,000 par-
ticipants. Encouragingly, only 91 incident infections were
detected, of which 27 occurred >30 days after the final dose of
Truvada was taken and 17 occurred within the first 3 months
of initiating PrEP, thus may have resulted from an earlier
exposure. This translates to an incidence rate of <1% per year.
These findings emphasize that PrEP adherence is critical for
success.
Who is using PrEP?
Laura Fitch (Abstract OA04.01)1 presented data from
AVAC’s Global PrEP tracker (PrEPWatch.org). Data from
the first quarter of 2018 indicated that 309,525 people have
initiated PrEP globally, with the highest numbers in North
America (71%) and sub-Saharan Africa (15%). In North
America, the majority of users are MSM, while the majority
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of users in sub-Saharan Africa are adolescent girls and young
women. Significant challenges to PrEP uptake and continu-
ation remain, even in areas of relatively high current usage.
Albert Liu (Abstract OA04.06)1 reported on PrEP awareness
among HIV-uninfected MSM and transgender women
(TGW) in San Francisco. In this study, 97% of MSM and
79% of TGW were aware of PrEP, yet only 40% of MSM and
15% of TGW had used PrEP despite high levels of health
insurance coverage and engagement in health care. Irene
Mukui (Abstract SY04.03)1 described progress and lessons
learned from the national rollout of PrEP in Kenya. As of
May 2017, only 1,425 Kenyans were taking PrEP com-
pared with 17,466 in August 2018. This impressive increase
was achieved through coordinated efforts of national and
international stakeholders, community members, and a
focus on specific geographic areas with high incidence
clusters.
Optimizing PrEP delivery
Renee Heffron (Abstract SY07.01)1 provided an over-
view of programs that incorporate oral PrEP into programs
addressing each stage of women’s reproductive health. For
those who desire pregnancy, PrEP can be provided efficiently
through safer conception programs. Additional opportunities
include integration of HIV prevention into antenatal care and
prevention of mother-to-child transmission, family planning
clinics and other places where emergency contraception or
abortion care is provided. Challenges to integration were
discussed, including low funding levels, nonsupportive pol-
icies, and low provider comfort. Nittaya Phanuphak (Ab-
stract SY07.04)1 described the successes of PrEP programs
led by key populations in Thailand. An impressive scale-up to
5,000 persons currently on PrEP, up from zero in 2014, was
achieved primarily due to community involvement in pro-
gram planning and implementation.
In a captivating presentation, Sarit Golub (Abstract
SY07.03)1 identified flaws in current risk-assessment
practices that contribute to stigma and alienation of potential
PrEP users. She described an alternative approach to dis-
cussing prevention, sexual health and HIV prevention op-
tions, counseling, in which clients and providers work
collaboratively to understand and address individual clients’
personal health priorities. This approach focuses on reasons
why people might want to take PrEP rather than focusing on
‘‘risk,’’ thereby reducing anxiety, increasing sexual satis-
faction, and improving the sense of control over one’s own
sexual health.
New ARVs and combination products for prevention
Raphael Landovitz (Abstract PL03.01)1 provided a
comprehensive overview of work to identify new systemic
PrEP products, including oral tenofovir alafenamide (TAF)/
FTC, injectable cabotegravir, bNAbs, the DPV vaginal ring,
implantable devices, and microneedle array patches. In the
DISCOVER trial, the safety and efficacy of daily oral
TAF/FTC are being compared with TDF/FTC. Trials are also
underway to evaluate the safety and efficacy of long-acting
injectable cabotegravir, which is being compared with daily
oral TDF/FTC in HPTN 083 and 084. In AMP trials, dis-
cussed elsewhere, the safety and efficacy of two different
doses of bimonthly passively infused VRC01 bNAb are being
compared with placebo. The ASPIRE and Ring trials previ-
ously demonstrated an*30% risk reduction conferred by the
DPV vaginal ring; subsequent open-label studies pointed to
greater, *50%, risk reduction. This product is currently
under regulatory evaluation. Finally, other novel approaches
under development include implants and microneedles,
which puncture the stratum corneum of the skin, allowing
direct delivery of drug into underlying tissues. These can take
several forms, including dissolving patches applied to the
skin. The range of products currently under development
provides hope that the future of biomedical HIV prevention
will involve user-empowering choices.
In an oral abstract session focused on the development of
new ARVs, James Cummins (Abstract OA15.01)1 provided
data on the PK-pharmacodynamic (PK-PD) properties of
drug-containing intravaginal rings (IVRs) containing the
second-generation integrase inhibitor MK-2048 alone or in
combination with vicriviroc, inserted and retained for 14 days
in Rhesus macaques. Results indicated the utility of the
macaque model for evaluating PK of MK-2048 and con-
firming its antiviral activity in vaginal tissues.
Treatment as Prevention
Undetectable equals untransmittable
Nelly Mugo (Abstract RT02.02)1 reviewed the science of
‘‘undetectable = untransmittable’’ (U =U), the observation
that suppressive ART has been convincingly and repeatedly
demonstrated to prevent sexual transmission of HIV. Based
upon multiple published studies, the World Health Organi-
zation now states that there is scientific ‘‘consensus that
people who have achieved and maintained an undetectable
viral load cannot transmit HIV sexually to their HIV negative
partners.’’ This is true irrespective of sexual practices (anal,
vaginal, and penile condomless penetrative sex), and within
the context of high transmission rates of other sexually
transmitted infection. However, she also stressed that com-
munity trials with weak linkage to ART treatment after a HIV
diagnosis have failed to produce similar reductions in HIV
incidence. Bruce Richman (Abstract RT02.05)1 emphasized
the transformative nature of U =U in dismantling HIV stigma
and providing a strong argument for universal health care
access. He emphasized that this message is difficult to com-
municate to the public at large, because ‘‘science doesn’t
have a publicist,’’ and there are many layers of long-standing
stigma to overcome.
Breastfeeding is an exception
Lena Serghides (Abstract RT02.03)1 reported that mother-
to-child transmission through breastfeeding appears to be an
exception to the rule of U=U. In the PROMISE trial of
>2,000 infants and their mothers, transmission rates of 0.6%
and 0.9% were seen within 12 and 24 months of breastfeed-
ing, respectively. Two of eight women who transmitted the
virus to their infants had confirmed undetectable plasma viral
load. Similarly, in the HPTN 046 trial, transmission among
women on ART was 0.5% at 18 months. Although cell-free
virus is largely eliminated by ART, latently infected CD4+
T-cells harboring cell-associated HIV DNA are not. Given
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the large amount of breastmilk consumed over a 6-month
period, infants may be exposed to many latently infected
CD4+ T-cells. Furthermore, some women have detectable
HIV RNA in breastmilk despite undetectable levels in plas-
ma. Thus, unfortunately U does not equal U in the context of
mother-to-child transmission. That said, breastfeeding deci-
sions in resource-poor settings must also weigh the impor-
tance of preventing malnutrition and diarrheal/pneumonia
diseases against the relatively low risk of HIV transmission
for women on suppressive cART.
The Future of Prevention Research
If a single sentiment permeated this third biennial HIVR4P
meeting, it may have been the sense of excitement at
the richness of the prevention pipeline, and the variety of
new prevention approaches and products in development.
Presentations on new prevention drugs and delivery sys-
tems—including inserts, implantables, gels, biodegradable
polymers, refillable reservoirs, osmotic pumps, and more—
drew crowds in Madrid. So did discussions about the op-
portunities and obstacles created by the increasing number of
prevention options available and in development. Among
these are the challenges of evolving trial design, the need to
understand user preference and evaluate health system ca-
pacity, managing product introduction and, of course, main-
taining financial and political support for biomedical HIV
prevention.
Trial design in the PrEP era
A major challenge for clinical trial design in the PrEP era is
that alternative PrEP agents are being compared with oral
TDF/FTC as the current standard of care. Sheena McCormack
(Abstract PL01.02)1 discussed novel trial designs to assess the
efficacy of new HIV prevention products in this environment.
Noninferiority studies require a larger sample size and longer
follow-up than traditional studies due to the high efficacy of
the TDF/FTC regimen. To overcome this challenge, back-
ground HIV incidence in the source population may be used as
an estimate of what incidence would be in a hypothetical
placebo group. This can be incorporated into a novel measure
of effectiveness, termed the averted infections ratio, which
compares the proportion of infections averted by the new drug
with that averted by TDF/FTC. Another approach, also ad-
dressed by Deborah Donnell (Abstract SY03.02),1 uses a
multiarm, multistage trial design, allowing multiple agents
and/or interventions to be compared with a single placebo
group, thereby reducing the number allocated to placebo.
From the regulatory perspective, Jeffrey Murray (US FDA)
(Abstract SY03.01)1 noted that noninferiority trials in women
may be difficult due to the absence of consistent historical
comparison data.
HIV prevention in women of childbearing age
Anne Lyerly (Abstract SY11.01)1 explored ethical con-
siderations regarding HIV prevention trials in women of
childbearing age. She showed how exclusion of pregnant
women from research studies means that knowledge about
the PDs and safety in pregnancy of medications used for
HIV treatment and prevention lags many years behind drug
approval.
Elaine Abrams (Abstract SY11.02)1 discussed recent
findings from the Tsepamo study that Dolutegravir (DTG)
use at conception may increase the risk of neural tube defects,
leading to WHO guidelines restricting DTG use among wo-
men of childbearing age to those using reliable contraception.
She drew parallels with historical restrictions on the use of
Efavirenz (EFV) by women of childbearing age, based upon
small numbers of cases of neural tube defects, which ham-
pered treatment rollout. After more than two decades, she
noted, EFV appears to be safe and is not associated with
neural tube defects. Sharon Hillier (Abstract SY11.04)1
asked ‘‘How much do any of us really understand about
risk?’’ She highlighted that while overall there had been a
balanced response to warnings regarding DTG use among
women of childbearing age, there are lessons that can be
learned. She discussed that after WHO warnings about DTG
use in pregnancy, the HPTN 084 study, examining the effi-
cacy of long-acting cabotegravir (CAB LA)—structurally
related to DTG—among women aged 18–45 has required its
participants to use long-acting contraception, meaning that
there will be data gaps on the safety of yet another PrEP drug
in pregnancy and periconception.
Choice in Prevention Options
‘‘Show Me The Ring’’
The themes of user choice and the need for more and better
user-controlled prevention options, including options that
can protect women without their partner’s knowledge, reso-
nated throughout the conference. Interest was high in the
status of the DPV ring, as well as in new rings and other
female-controlled products in development. Updates on
vaginal and rectal microbicides also filled conference rooms
in Madrid, with delegates anxious to learn the latest on these
long-sought-after forms of prevention.
Craig Hendrix (Abstract PL03.02)1 reviewed the pipeline
for on-demand, topical (vaginal/rectal) PrEP. He summarized
evidence that such products can be effective, arguing that
choice from among a range of prevention options leads to
increased uptake, drawing parallels with contraception. He
described vaginal and anal microbicides in development,
beginning with the Pod-IVR, a vaginal ring that can deliver
flexible drug combinations. Studies published in 2018 re-
vealed that some drugs (FTC and MVC) can achieve pro-
tective levels in the rectum when delivered through pod
vaginal rings. Other novel products included fast-dissolving
vaginal films, vaginal and rectal inserts, and numerous mul-
tipurpose formulations that provide protection against other
STIs and/or deliver contraceptive agents. At least eight phase
1 trials of rectal microbicides have been or will soon be
conducted. Several of these are aiming to be behaviorally
congruent; that is, by adding PrEP to a product that people
already use as part of their sexual routine, in this case lubri-
cants and douches used by >85% and >75% of MSM, re-
spectively. Studies have shown promising feasibility and
acceptability of a rectal microbicide douche for MSM. Dr.
Hendrix finished with a call to ensure that microbicide de-
velopment continues to be a priority, to provide as wide a
range of HIV prevention choices as possible.
Presented by Elizabeth Montgomery (Abstract OA04.04),1
the Quatro study of 200 young women in Zimbabwe and South
Africa tested the acceptability of four vaginal placebo delivery
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modalities: monthly rings and precoital films, inserts and
gels. The findings from adherence marker evaluation con-
firmed that most women did use the products, over half of the
women who chose an on-demand product used them with
sex, and older women were more adherent. Findings from the
study highlighted that users desired multiple prevention op-
tions; accordingly, women should be given various options to
choose from.
Adolescents in South Africa account for 40% of new in-
fections, yet little is known about preferred prevention mo-
dalities in this group. Findings from UChoose, a study of
prevention choices in adolescent women ages 15–19, were
presented by Katherine Gill (Abstract OA05.06LB).1 This
open-label, randomized crossover study used licensed con-
traceptive modalities (monthly vaginal rings; injectables;
oral contraceptives) to assess acceptability and preferences.
Results suggested that long-acting injectable PrEP would
have the highest acceptability, followed by vaginal rings, and
finally, oral pills.
‘‘Give Me Prevention That Lasts’’
Continuing with the theme of choice in prevention, those
seeking news on systemic prevention approaches encoun-
tered an expanding universe of data on long-acting PrEP at
HIVR4P, including the first tail-phase data on long-acting
injectable cabotegravir in women.
Reported by Elizabeth Tolley (Abstract OA05.01),1 A
phase 2 study by the HIV Prevention Trials Network, HPTN
077, sought to test acceptability of CAB LA in HIV unin-
fected, low-risk men and women in Brazil, Malawi, South
Africa, and the United States. There was a strong preference
for long-acting injectable PrEP at both baseline and follow-
up, particularly from participants outside the United States.
Susan Ford (Abstract OA15.05)1 presented a CAB Po-
pulation PKs model that included intrinsic and extrinsic
factors, developed with data from phase 1/2 studies and
simulations that can be used to inform PrEP phase 3 dosing
strategies. Results revealed that the CAB LA absorption rate
differs between males and females, and provided informa-
tion that can be used to develop recommendations for re-
initiation strategies for those with prolonged interruptions in
dosing.
Finally, Raphael Landovitz (Abstract OA15.06LB)1 and
colleagues provided results from HPTN 077 evaluating tail-
phase safety, tolerability, and PKs of long-acting injectable
CAB in HIV-uninfected individuals. The apparent half-life of
CAB LA for females was significantly longer compared with
males, and was also influenced by body mass index. The
median time to the lower limit of quantification (LLOQ) was
66.3 weeks for females and 42.7 weeks for males. At 76
weeks after the final injection, 58% of females and 87% of
males had levels below the LLOQ.
Concluding Messages
In the two years since the HIVR4P 2016 conference,
consistent progress has been made toward improving and
expanding HIV prevention strategies. As prevention science
advances, however, the challenges of maintaining the polit-
ical will and funding to support a global movement to end the
AIDS epidemic come into even sharper focus.
New strategies of vaccine design are following several
well-defined routes to reach 50%–60% efficacy, suggested as
the lowest acceptable threshold for a vaccine candidate to be
used in combination with other prevention strategies. In
parallel, bNAbs are emerging as important new tools in the
repertoire of feasible prevention strategies. For both these
approaches, data from ongoing studies will be eagerly
awaited at the next HIVR4P meeting.
Condom use, VMMC, prevention of mother-to-child
transmission, TasP, and PrEP have also made significant
strides as nonvaccine-based strategies for HIV prevention.
Multipurpose products, providing protection against HIV and
pregnancy, will provide exciting new options for women.
It was clear from discussions in the meeting rooms, poster
sessions, and hallways that hope persists that the future of
biomedical HIV prevention will include a wide array of
prevention modalities. Behavioral research has demonstrated
that preferences for specific modalities vary greatly, and the
availability of multiple options may help us to develop a
wider range of implementation strategies to reach more men
and women worldwide. Ensuring that scientific advances
progress from the laboratory to clinical trials to the com-
munity remains a challenge that HIVR4P participants are
poised to address.
The next HIVR4P conference will be held in Cape Town,
South Africa, in October 2020.
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